IC-MPGN
Clinical trials for IC-MPGN explained in plain language.
Never miss a new study
Get alerted when new IC-MPGN trials appear
Sign up with your email to follow new studies for IC-MPGN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage, compared to a placebo. Participants received injections twice a week …
Matched conditions: IC-MPGN
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 05:04 UTC
-
New hope for transplant patients with rare kidney disease
Disease control CompletedThis study tested a drug called pegcetacoplan in 13 adults whose rare kidney disease (C3G or IC-MPGN) came back after a kidney transplant. The goal was to see if the drug could safely reduce signs of disease in kidney tissue. Participants received the drug or standard care, and r…
Matched conditions: IC-MPGN
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC